HC Wainwright restated their buy rating on shares of Akebia Therapeutics (NASDAQ:AKBA – Free Report) in a research note released on Wednesday morning, Benzinga reports. The firm currently has a $7.50 price target on the biopharmaceutical company’s stock.
Akebia Therapeutics Stock Up 0.6 %
Shares of Akebia Therapeutics stock opened at $1.59 on Wednesday. Akebia Therapeutics has a twelve month low of $0.78 and a twelve month high of $2.48. The stock has a market cap of $333.26 million, a price-to-earnings ratio of -6.91 and a beta of 0.77. The company’s fifty day moving average is $1.41 and its 200 day moving average is $1.28.
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. The firm had revenue of $43.65 million for the quarter, compared to the consensus estimate of $45.61 million. During the same period last year, the company posted ($0.06) EPS. As a group, equities analysts anticipate that Akebia Therapeutics will post -0.19 earnings per share for the current fiscal year.
Institutional Trading of Akebia Therapeutics
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.
Featured Stories
- Five stocks we like better than Akebia Therapeutics
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Texas Roadhouse Stock Steering for New Highs This Year
- Investing In Preferred Stock vs. Common Stock
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Do ETFs Pay Dividends? What You Need to Know
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.